A Phase 2 interventional study of NKT2152 and palbociclib in ccRCC, Clear Cell Renal Cell Carcinoma and Kidney Cancer, sponsored by NiKang Therapeutics, Inc.. Terminated at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-12.
Sponsored by NiKang Therapeutics, Inc. · Phase 2, Interventional, and Treatment
The goal of the Lead-in phase of the study is to evaluate the safety, efficacy, pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy. The goal of the Expansion phase of the study is to evaluate the safety, efficacy, PK at the selected RDE and identify the RP2D for NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy.
This is a Phase 2 open-label, multicenter, global study of NKT2152. This study is designed as two phases: a Lead-in phase and an Expansion phase. Patients must be 18 years or older, with advanced or metastatic clear cell renal cell carcinoma (ccRCC). Eligible patients must have progressed or relapsed after at least 1 prior anti-vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) systemic therapy and 1 immune checkpoint inhibitor (ICI) for advanced or metastatic ccRCC alone or in combination.
The Lead-in phase is designed as a dose escalation phase to evaluate the safety, efficacy, pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in combination with palbociclib and sasanlimab in advanced or metastatic ccRCC patients who received prior therapy.
The subsequent Expansion phase will evaluate the safety, efficacy, PK at the selected RDE and identify the RP2D for NKT2152 in combination with palbociclib and sasanlimab in advanced or metastatic ccRCC patients who received prior therapy.
Exclusion Criteria:
Lead-in Doublet assesses safety of oral dosing NKT2152 at increasing dosage levels in combination with palbociclib to determine a recommended dose for expansion (RDE).
Drug: NKT2152 · Drug: palbociclib
Lead-in Triplet assesses the safety of two doses of NKT2152 identified in the Doublet arm (RDE and RDE-1) by orally dosing ccRCC patients with NKT2152 in combination with palbociclib and sasanlimab
Drug: NKT2152 · Drug: palbociclib · Other: sasanlimab
Subjects randomized to Arm 1 will receive the Doublet combination (NKT2152 in combination with palbociclib) to provide an assessment of anti-tumor activity and to determine the RP2D.
Drug: NKT2152 · Drug: palbociclib
Subjects randomized to Arm 2 will receive the Triplet therapy (NKT2152 in combination with palbociclib and sasanlimab) to provide an assessment of anti-tumor activity and to determine the RP2D.
Drug: NKT2152 · Drug: palbociclib · Other: sasanlimab
Oral HIF2a inhibitor
a cyclin-dependent kinases (CDK) 4 and 6 inhibitor
Also known as: IBRANCE®
an immunoglobulin G4 (IgG4) monoclonal antibody that blocks PD-1; a solution for injection for subcutaneous administration
Number of Participants with Dose Limiting Toxicity (DLT) events during the DLT monitoring period (first 28 days of dosing) in the Lead-in Phase
DLTs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5 .0.
Time frame: 28 days
Objective Response Rate (ORR) determined by the Investigator
ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Time frame: 1 years
Progression-free survival (PFS)
PFS defined as the time from the date the participant started study drug to the date the participant experiences an event of disease progression or death.
Time frame: 2 years
Duration of Response (DOR)
Duration of overall response is defined as the time from the date of first documented CR or PR, assessed by investigator and based on RECIST v. 1.1, to the documented date of progressive disease (PD) or death, whichever occurred first.
Time frame: 1 years
Time to Response (TTR)
TTR is defined as the time from first dose to the first documented CR or PR which is subsequently confirmed.
Time frame: 1 years
Overall Survival (OS)
OS defined as the time from the date the participant started study drug to death for any reason.
Time frame: 2 years
Clinical Benefit Rate (CBR)
CBR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) or a stable disease (SD) of 8 weeks or longer based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Time frame: 1 years
Number of Participants with Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a patient and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.
Time frame: 2 years
Maximum observed plasma concentration (Cmax) of NKT2152
Maximum observed plasma concentration (Cmax) of NKT2152
Time frame: 1 years
Time to maximum observed plasma concentration of NKT2152 (Tmax)
Time to maximum observed plasma concentration of NKT2152 (Tmax)
Time frame: 1 years
Observed trough concentration of NKT2152 (Ctrough)
Observed trough concentration of NKT2152 (Ctrough)
Time frame: 1 years
Area under the plasma concentration time curve (AUC0-t) of NKT2152, and accumulation ratio (RAC)
Area under the plasma concentration time curve (AUC0-t) of NKT2152, and accumulation ratio (RAC)
Time frame: 1 years
Maximum observed plasma concentration (Cmax) of palbociclib
Maximum observed plasma concentration (Cmax) of palbociclib
Time frame: 1 years
Time to maximum observed plasma concentration of palbociclib (Tmax)
Time to maximum observed plasma concentration of palbociclib (Tmax)
Time frame: 1 years
Observed trough concentration of palbociclib (Ctrough)
Observed trough concentration of palbociclib (Ctrough)
Time frame: 1 years
Area under the plasma concentration time curve (AUC0-t) of palbociclib, and accumulation ratio (RAC)
Area under the plasma concentration time curve (AUC0-t) of palbociclib, and accumulation ratio (RAC)
Time frame: 1 years
Observed trough concentration of sasanlimab (Ctrough)
Observed trough concentration of sasanlimab (Ctrough)
Time frame: 1 years
Maximum observed plasma concentration (Cmax) of sasanlimab
Maximum observed plasma concentration (Cmax) of sasanlimab
Time frame: 1 years
Plan to share: No — IPD are not planned to be shared at this time
No publications or documents are linked to this record.
This study is terminated, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NiKang Therapeutics, Inc.